Lushang Freda PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Lushang Freda PharmaceuticalLtd de 21.9% y 11.7% por año respectivamente. Se prevé que el BPA crezca en un 21.7% al año. Se espera que la rentabilidad financiera sea de 11.2% en 3 años.

Información clave

30.0%

Tasa de crecimiento de los beneficios

29.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Real Estate	30.2%
Tasa de crecimiento de los ingresos	15.3%
Rentabilidad financiera futura	10.4%
Cobertura de analistas	Good
Última actualización	01 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Apr 16

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Mar 28

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 04

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Feb 27

Previsiones de crecimiento de beneficios e ingresos

SHSE:600223 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	6,381	585	128	983	8
12/31/2025	5,569	487	53	578	10
12/31/2024	4,738	377	2,467	1,850	8
3/31/2024	4,197	233	213	418	N/A
12/31/2023	4,579	303	263	474	N/A
9/30/2023	7,817	130	-127	98	N/A
6/30/2023	10,590	47	84	350	N/A
3/31/2023	12,741	108	1,263	1,442	N/A
12/31/2022	12,951	45	832	998	N/A
9/30/2022	14,543	13	3,070	3,273	N/A
6/30/2022	13,131	240	4,103	4,293	N/A
3/31/2022	12,140	342	5,970	6,250	N/A
12/31/2021	12,363	362	6,567	6,848	N/A
9/30/2021	12,929	729	7,473	7,700	N/A
6/30/2021	14,137	710	7,719	7,944	N/A
3/31/2021	13,915	662	5,543	5,712	N/A
12/31/2020	13,615	639	4,291	4,448	N/A
9/30/2020	10,316	572	4,680	4,841	N/A
6/30/2020	9,817	482	39	174	N/A
3/31/2020	10,307	364	-4,831	-4,759	N/A
12/31/2019	10,289	345	-3,367	-3,307	N/A
9/30/2019	10,373	222	-5,546	-5,516	N/A
6/30/2019	10,159	195	-2,295	-2,262	N/A
3/31/2019	9,261	184	3,184	3,222	N/A
12/31/2018	8,821	162	2,062	2,095	N/A
9/30/2018	10,105	166	1,120	1,207	N/A
6/30/2018	8,694	159	1,489	1,571	N/A
3/31/2018	8,476	129	278	360	N/A
12/31/2017	8,287	128	N/A	1,637	N/A
9/30/2017	7,576	102	N/A	3,215	N/A
6/30/2017	7,909	98	N/A	-1,495	N/A
3/31/2017	7,370	94	N/A	-1,127	N/A
12/31/2016	7,646	92	N/A	-2,468	N/A
9/30/2016	7,151	107	N/A	-4,768	N/A
6/30/2016	5,870	101	N/A	-1,056	N/A
3/31/2016	6,118	103	N/A	-1,723	N/A
12/31/2015	5,864	112	N/A	-1,798	N/A
9/30/2015	5,109	166	N/A	-991	N/A
6/30/2015	6,365	205	N/A	-1,002	N/A
3/31/2015	5,908	207	N/A	-1,042	N/A
12/31/2014	5,682	206	N/A	-2,363	N/A
9/30/2014	6,387	287	N/A	-2,457	N/A
6/30/2014	5,790	273	N/A	-2,511	N/A
3/31/2014	5,477	272	N/A	-2,356	N/A
12/31/2013	5,293	263	N/A	-1,088	N/A
9/30/2013	4,874	296	N/A	-989	N/A
6/30/2013	4,125	258	N/A	-343	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.9% al año) de 600223 es superior a la tasa de ahorro (2.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (30.1% al año) de 600223 crezcan más rápidamente que el mercado CN (24.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 600223 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (15.5% al año) de 600223 crezcan más rápidamente que los del mercado CN (14.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 11.7% al año) de 600223 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 600223 sea baja dentro de 3 años (11.2%).

Lushang Freda PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 8.1% to CN¥13.52

Price target increased by 7.3% to CN¥13.42

Price target increased by 8.3% to CN¥13.29

Price target decreased to CN¥11.17

Price target decreased to CN¥12.27

Price target decreased to CN¥12.87

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.13 in 1Q 2023)

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Lushang Life Services Co., Ltd. (SEHK:2376) agreed to acquire Shandong Lujian Property Management Limited from Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) for RMB 4.9 million.

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Investor sentiment deteriorates as stock falls 16%

Lushang Freda Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

New major risk - Financial position

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023

New major risk - Dividend sustainability

Lushang Freda Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Price target increased by 8.1% to CN¥13.52

Price target increased by 7.3% to CN¥13.42

Price target increased by 8.3% to CN¥13.29

Price target decreased to CN¥11.17

Lushang Health Plans to Sell Real Estate Assets to Controlling Shareholder or Affiliates

Price target decreased to CN¥12.27

Third quarter 2022 earnings released: CN¥0.033 loss per share (vs CN¥0.19 profit in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.23 in 2Q 2021)

Price target decreased to CN¥12.87

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to CN¥16.16

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.17 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.18 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥16.10

First quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.06 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.34 in FY 2019)

Lushang Health Industry Development Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021

Investor sentiment improved over the past week

New 90-day high: CN¥14.15

New 90-day high: CN¥12.58

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥9.21

Market bids up stock over the past week

Third quarter earnings released

Lushang Health Industry Development Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥9.66

Earnings released

New 90-day high - CN¥15.60

Lushang Health Industry Development Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento